

1

2 **Lack of protective effect of chloroquine derivatives on COVID-19**
3 **disease in a Spanish sample of chronically treated patients.**

4 **Marina Laplana¹, Oriol Yuguero^{2,3}, Joan Fibla^{3,4,*}**

5 ¹ Departament de Ciència Animal, Universitat de Lleida, Lleida, Spain

6 ² Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain

7 ³ Institut de Recerca Biomedica de Lleida, Lleida, Spain

8 ⁴ Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Lleida, Spain

9

10 M. Laplana, PhD: marina.laplana@udl.cat. ORCID: 0000-0002-2548-0704

11 O. Yuguero, PhD, MD: oriolyuguero@gencat.cat. ORCID: 0000-0002-3433-8005

12 J. Fibla, PhD : joan.fibla@udl.cat. ORCID: 0000-0002-3255-2227

13

14

15 *** Corresponding author:**

16 E-mail: joan.fibla@udl.cat (JF)

17

18 **Running heads:** No prophylactic effect of hydroxychloroquine against COVID-19 disease

19

20 Abstract

21 **Background:** The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We
22 evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals.

23 **Methods:** We performed a survey addressed to patients regularly taking chloroquine and its
24 derivatives for the control of their autoimmune diseases. The survey was distributed with special
25 attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to
26 the general population. A sample of untreated subjects was matched to the treated group according to
27 sex, age range and incidence region. COVID-19 disease prevalence was compared between treated
28 and untreated-matched control sample.

29 **Results:** A total of 319 surveys of patients regularly taking chloroquine and its derivatives were
30 recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was
31 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community
32 exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated
33 (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value=0.027).

34 **Conclusion:** We did not find differences of reported COVID-19 cases between treated and untreated
35 groups, indicating a lack of protection by regular administration of chloroquine and its derivative
36 drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take
37 chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection
38 measures as the general population.

39 **Keywords:** chloroquine, COVID-19 prevalence, hydroxychloroquine, prophylaxis, SARS-CoV-2

40

41 **Introduction**

42 The search for an effective treatment against SARS-CoV-2 infection has emerged as a worldwide
43 priority. A promising strategy to fight the virus causing the newest pandemic is the identification of
44 already available drugs active against other diseases that can be effective also against this new
45 SARS-CoV-2 infection [1].

46 We present here an evaluation of the potential protective effect of chloroquine and its derived drugs
47 on the prevalence of COVID-19 in patients undergoing an active treatment with these drugs.

48 Chloroquine and its derived drugs such as hydroxychloroquine have shown *in vitro* and *in vivo*
49 effectiveness against viral infections such as SARS [2], influenza A H5N1, and Zika. Chloroquine is
50 believed to interfere with both the entry and exit of viruses from cells hosts, as well as in the
51 manifestation of acute respiratory syndrome. The virus enters the cells through binding to the
52 angiotensin-converting enzyme 2 (ACE2). Chloroquine can reduce ACE2 glycosylation, thereby
53 preventing viruses from effectively binding to cells [3]. On the other hand, chloroquine accumulates
54 in lysosomes, increasing the endosome pH levels which interferes with the viral particle release
55 process [4]. In addition, chloroquine could block the production of proinflammatory cytokines, thus
56 preventing the pathway that subsequently leads to acute respiratory syndrome [5]. Two recent clinical
57 trials have presented inconclusive evidence on the effectiveness of chloroquine treatment in COVID-
58 19 disease in Chinese [6] and French [7] populations. Both studies have supported the use of
59 chloroquine or chloroquine derivatives against COVID-19, however, the design and conclusions of
60 both studies have been questioned [8].

61 Chloroquine and its derivatives such as chloroquine phosphate or hydroxychloroquine are commonly
62 used in the treatment of autoimmune diseases. Not without serious side effects, the use of these drugs

63 under medical prescription is widely spread. It has been proposed hydroxychloroquine as a
64 prophylaxis treatment against SARS-CoV-2 infection for exposed caregivers [9-11]. Our hypothesis
65 is that if chloroquine treatment is effective against SARS-CoV-2 infection, those patients following
66 an active chloroquine or derivative drug treatment would be protected against the infection or against
67 COVID-19 adverse effects. Thus, our study aims to test this hypothesis by evaluating the incidence
68 of COVID-19 disease in the population according to chloroquine treatment subgroups through a
69 survey.

70 **Material and methods**

71 **Survey design and data collection**

72 A survey was distributed in Spanish and Catalan languages and conceived to be conducted
73 electronically via smartphone or personal computer, and therefore it was also designed to ensure
74 accessibility and simplicity to facilitate its completion. A copy of the original survey in Spanish and
75 Catalan languages and a translated English version can be found as Supporting Information (S1-S3
76 Surveys). Information about the project and a link to the URL of the survey were disseminated in the
77 press and via social media and email, with special attention to Spanish patient associations centered
78 on autoimmune diseases and rheumatology. The survey included demographic questions about
79 gender, age range, and Autonomous Community of residence, as well as questions pertaining to
80 health-status outcomes such as treatment, COVID-19 diagnosis and symptoms due to COVID-19
81 infection. In addition, questions about infection diagnosis and symptoms in close relatives and
82 friends were also included. Because the first cases of COVID-19 were reported in Spain in March
83 2020, our survey collects cases that occurred between March and May 2020.

84 In order to evaluate the effect of chloroquine and its derivatives on COVID-19 infection risk, we
85 have taken advantage of the unique available source of people receiving this drug as a chronic
86 treatment, the group of patients with autoimmune diseases. However, at time of recruitment a very
87 low percentage of COVID-19 patients had an autoimmune disease (less than 1%) [12], while age,
88 gender and region of origin were the main known factors affecting SARS-CoV-2 infection in Spain's
89 autonomies. In addition, the recruitment of untreated cases had to comprise a large number of
90 individuals to be able to do the proper matching between treated and untreated individuals, being the
91 treated patients the limiting group. According to this, we decided to use individuals from the general
92 population as untreated cases considering age, gender and Autonomous Community of residence as
93 the main selection criteria for recruitment.

94 Individuals of any age above legal age (18 years old) with residence in Spain were eligible for
95 inclusion in the study. Individuals undergoing a stable chloroquine or derived drug treatment before
96 the COVID-19 pandemic were classified as treated (treated group) while individuals without
97 treatment and those beginning acute treatment in the last three months (January-March) were
98 classified as untreated (untreated group). Individuals beginning acute treatment were receiving it as a
99 treatment after being infected with SARS-CoV-2, thus, they were not under treatment prior to
100 infection.

101 The Clinical Research Ethics Committee of the Hospital Universitari Arnau de Vilanova in Lleida
102 approved the study (Ref: CEIC-2257).

103 **Statistical analysis**

104 Statistical analyses were performed with R software (v3.6.0) and IBM SPSS v21 (IBM corporation,
105 NY, USA). Prior to the analysis, reported autonomy of residence in Spain were grouped according to
106 COVID-19 incidence as stated in June 1 by the Spanish Ministry of Health [13] as follows: Incidence

107 region 1 (incidence<200/100,000 inhabitants) that includes Andalucía, Canarias, Ceuta, Illes Balears,
108 Melilla and Región de Murcia; Incidence region 2 (incidence 200-500/100,000 inhabitants) that
109 includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de
110 Asturias; Incidence region 3 (incidence 500-1,000/100,000 inhabitants) that includes Castilla y León,
111 Castilla-La Mancha, Catalunya, Euskadi and Navarra; and Incidence region 4
112 (incidence>1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja. Age
113 categories were assigned according to the following age ranges: 18-50, 51-65 and >65 years old.
114 Data on symptoms related to COVID-19 infection were collected and used to assign individuals as
115 suspected COVID-19 cases when reporting loss of taste or smell and/or three or more COVID-19
116 associated symptoms [14].

117 A sample of untreated subjects was matched to the treated group according to sex, age range and
118 incidence region with e1071 R package. The matching process was repeated using a bootstrap
119 strategy and re-sampling of the untreated-matched dataset was repeated 1,000 times to obtain the
120 distribution and mean values of the descriptive statistics such as age range, gender, incidence region
121 and declared COVID-19 prevalence. Statistical analysis was performed to validate the appropriate
122 distribution of the demographic characteristics within each group what rules out the possibility of a
123 bias towards one of the variables. In addition, tests between treated and untreated groups were used
124 to confirm the proper matching of the subjects. Comparisons were performed by Fisher exact test. P-
125 value <0.05 was considered statistically significant. Comparison of differences among treated group
126 and 1000 replicates of untreated-matched groups was performed by Fisher exact test. In addition, the
127 difference between the two proportions and a 95% confidence interval for this difference was
128 performed using the comparison of proportions method (Chi-squared test).

129 **Results**

130 Overall, 2295 individuals completed the surveys between May and June 2020. From these, data
 131 collection was complete, with all key data for the study, for 2161 individuals (94.2%). These
 132 completed surveys were checked for inconsistencies and possible duplicated values as well as to
 133 fulfil the eligibility criteria, 11 entries were excluded from further analysis. The final number of
 134 completed surveys used for the study was 2150. A copy of the anonymized data set is provided in
 135 Supplementary Information (S1 Data). Among them, 319 (14.8%) were from patients following an
 136 active chloroquine or derived drug treatment and have been included in the treatment group, and
 137 1831 (85.2%) have been included in the untreated group and serves as the source to obtain the
 138 untreated-matched subgroups. We note that 94% of the treatment group individuals were following a
 139 hydroxychloroquine treatment.

140

Table 1 - Demographic characteristics of persons taking chloroquine or derivatives (treated) and matched control sample (untreated) according to their declared COVID-19 status

	Treated (n=319)				Untreated (n ^a =319)				Treated vs Untreated
	COVID-19 (+)	COVID-19 (-)	Totals	P-value	COVID-19 (+)	COVID-19 (-)	Totals	P-value	P-value
Age range, n (%)									
18-50	9 (4.7)	182 (95.3)	191	0.433	6.7 (3.5)	185.4 (96.5)	192.2	0.999	0.981
51-65	8 (7.1)	105 (92.9)	113		3.9 (3.5)	107.5 (96.5)	111.3		
> 65	0 (0.0)	15 (100.0)	15		0.3 (2.1)	15.2 (97.9)	15.5		
Total	17 (5.3)	302 (94.7)	319		10.9 (3.4)	308.1 (96.6)	319		
Sex, n (%)									
Male	1 (4.8)	20 (95.2)	21	0.905	1.1 (5.0)	20.2 (95.0)	21.2	0.973	1.000
Female	16 (5.4)	282 (94.6)	298		9.8 (3.3)	287.9 (96.7)	297.8		
Total	17 (5.3)	302 (94.7)	319		10.9 (3.4)	308.1 (96.6)	319		
Incidence region ^b , n (%)									
R1	1 (2.4)	40 (97.6)	41	0.420	0.0 (0.0)	41.1 (100.0)	41.1	0.275	0.215
R2	1 (2.8)	35 (97.2)	36		1.0 (3.4)	28.7 (96.6)	29.7		
R3	11 (5.4)	193 (94.6)	204		6.1 (2.7)	218.8 (97.3)	225.0		
R4	4 (11.4)	31 (88.6)	35		3.2 (15.9)	17.0 (84.1)	20.2		
Unknown	0 (0.0)	3 (100.0)	3		0.5 (17.3)	2.5 (82.7)	3.0		
Total	17 (5.3)	302 (94.7)	319		10.9 (3.4)	308.1 (96.6)	319		
Community exposition, n (%)									
Exposed ^c	8 (17.0)	39 (83.0)	47	<0.001	8.2 (13.3)	53.3 (86.7)	61.5	0.027	0.300

Unexposed	7 (3.2)	210 (96.8)	217	2.2 (1.1)	204.4 (98.9)	206.6
Unknown	2 (3.6)	53 (96.4)	55	0.5 (1.0)	50.4 (99.0)	50.9
Total	17 (5.3)	302 (94.7)	319	10.9 (3.4)	308.1 (96.6)	319

COVID-19: disease caused by SARS-CoV-2 infection.

^a Mean after 1000 replicates of matched untreated control samples.

^b Regions grouped by incidence of COVID-19. IR1 (incidence <200/100,000 inhabitants) that includes Andalucía, Canarias, Ceuta, Illes Balears, Melilla and Región de Murcia; IR2 (incidence 200-500/100,000 inhabitants) that includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de Asturias; IR3 (incidence 500-1,000/100,000 inhabitants) that includes Castilla y León, Castilla-La Mancha, Catalunya, Euskadi and Navarra; and IR4 (incidence >1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja.

^c Exposed were those individuals declaring a COVID-19 positive case in a close family member or flatmate.

141 142

143 The main descriptive characteristics of both treated (n=319) and untreated-matched (n=319)
144 subgroups, arranged according to their declared COVID-19 status, are reported in Table 1.
145 Distribution of declared COVID-19 status did not differ significantly within age group, gender and
146 incidence region (Table 1). In contrast, having a community exposition (defined as those individuals
147 declaring a COVID-19 positive case in a close family member or flatmate) was associated with a
148 greater prevalence of COVID-19 disease when compared with non-exposed individuals in both
149 treated (17.0%, 95%CI 12.9%-21.1% vs. 3.2%, 95%CI 1.3%-5.2%; p-value<0.001) and untreated
150 subgroups (13.4%, 95%CI 9.6%-17.1% vs. 1.1%, 95%CI 0%-2.2%; p-value=0.027) (Table 1 and Fig
151 1). Furthermore, we evaluated the distribution of the descriptive characteristics between treated and
152 untreated groups denoting no statistical significant differences, and thus, confirming the appropriate
153 matching of the groups (Table 1).

154

155 Figure 1.- Percentage of declared COVID-19 cases according to treatment status and community exposition.
156 Treated group refers to patients regularly taking chloroquine and its derivatives. Exposed are those individuals
157 declaring a COVID-19 positive case in a close family member or flatmate. Error bars depict the 95%
158 confidence interval.

159

160 The prevalence of declared COVID-19 status in the treated group was 5.3% (95%CI 2.9-7.8) and the
161 mean prevalence among the untreated-matched groups was 3.4% (95%CI 1.4-5.4). Testing
162 differences among treated and 1000 replicates of untreated-matched groups reveals significant
163 differences only in 28 comparisons ($P = 0.972$). In addition, the difference of proportions of declared
164 COVID-19 cases between both groups did not reach statistical significance (difference 1.9%, 95%CI:
165 0-5.3; $P = 0.240$). Furthermore, the prevalence of suspected COVID-19 patients in treated subjects was
166 of 18.8% (95%CI 14.5-23.1) and the mean prevalence among the untreated-matched groups was
167 15.7% (95%CI 11.7-19.7). Neither the comparison of the prevalence nor the distribution of the
168 difference of declared COVID-19 cases among groups showed significant differences. These figures
169 are nearly similar to those recently found in the study of the seroprevalence of IgG antibodies against
170 SARS-CoV-2 in the Spanish population showing an estimated prevalence of 5% (95%CI 4.7%-
171 5.4%), and a prevalence of suspected COVID-19 cases of nearly 20% [14].

172 **Discussion**

173 Our results show no differences in COVID-19 prevalence among untreated and chronically treated
174 individuals with chloroquine or derivative drugs. Independently of the exposure, both groups showed
175 the same prevalence of COVID-19 disease or suspected COVID-19 disease according to symptoms.
176 We must note that we found a clear association between the COVID-19 disease prevalence and
177 exposure to a close family member or flatmate positive for COVID-19 in both, treated and untreated
178 subjects, that points to a lack of any protective effect on SARS-CoV-2 infection attributable to
179 chronic treatment with chloroquine or derivative drugs.

180 We should mention some limitations of our study such as a limited power to detect small changes in
181 prevalence between treatment groups. However, the design of this study addressed the need to collect
182 and analyse data within a particularly short period of time due to the rapid onset and progression of

183 the pandemic, as well as the urgency of identifying and evaluating rapidly possible therapies, thus
184 partially compensating the reduced sample size. The prevalence of COVID-19 found in our study is
185 similar to the seroprevalence of IgG antibodies against SARS-CoV-2 in the Spanish population [14],
186 which is higher than the reported COVID-19 prevalence in the general population based on RNA's
187 virus detection [13]. This difference could be attributed to self-reported disease and the diagnosis of
188 COVID-19 by medical practitioners, which in many cases does not involve results of diagnostic tests
189 due to the lack of such tests. Finally, we could not eliminate completely the possibility of some bias
190 due to the intrinsic condition of the individuals within the treatment group that are undergoing
191 chloroquine or derivative drug treatment due to other diseases that alter their health status and may
192 have different comorbidities. A previous study reported a low portion of autoimmune diseases
193 patients as COVID-19 cases (less than 1%) [12]. On the other hand, the main factors reported to
194 affect SARS-CoV-2 infection were age, gender and region of origin in Spain's autonomies. Despite
195 the lack of evidence that autoimmune diseases affect the risk of infection, we cannot completely
196 discard a possible bias caused by the autoimmune status of cases. However, we assume a negligible
197 effect caused by this possible bias in comparison with the other matching parameters such as sex, age
198 and place of residence, that have allowed us to obtain a large and representative N of the different
199 population groups. Finally, we lack information about chloroquine or hydroxychloroquine treatment
200 doses for each subject what, in case of low doses could not be enough to show an effect in the
201 prevention of COVID-19. However, based on the Spanish Agency for Medicines and Health
202 Products, the standard treatment for autoimmune diseases such as lupus or rheumatoid arthritis
203 usually ranges from 200 to 600mg of hydroxychloroquine per day, what is in line with the dose given
204 as a treatment to COVID-19 patients. Thus, the doses taken regularly by the subjects of the study and
205 the doses used as treatment for infected patients should not differ significantly what makes us think
206 that this should not represent a major limitation of our study.

207 However, our results are in line with a recent study conducting a randomized trial that reported no
208 effect of hydroxychloroquine when used as a post exposure prophylaxis for COVID-19 [15].

209 **Conclusion**

210 All these data together point towards a lack of a protective effect of chloroquine or derivative drugs
211 as a prophylaxis for COVID-19, including prophylactic treatment before and after exposure in
212 patients with autoimmune diseases or other chronic conditions that require these treatments, and
213 potentially increase the risk for SARS-CoV-2 infection per se. Of relevance, data indicates that
214 people that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must
215 take the same protection measures as the general population. These data should be considered in the
216 prevention and treatment protocols made by health policymakers for the management of the disease
217 in new outbreaks. Finally, efficacy of chloroquine and its derivatives in preventing SARS-CoV-2
218 infection will be determined by upcoming clinical trials.

219

220 **Supporting information**

221 S1 Text. Survey questions in Spanish.

222 S2 Text. Survey questions in Catalan.

223 S3 Text. Survey questions translated to English.

224 S1 Data. Anonymised Data set

225

226 **Acknowledgments**

227 This study and the research behind it would not have been possible without the selfless contribution
228 of all the people who participated and that took time to respond the survey. We would like to thank
229 Dr. Serafi (Tapi) Piñol for his valuable comments and suggestions.

230 **Author Contributions**

231 JF created the online survey, conceived and design the study. ML and JF were responsible for data
232 analysis. All authors were involved in the development of the survey, contributed to the writing of
233 the manuscript and approved the final draft

234 **Conflict of Interest**

235 The authors declare that the research was conducted in the absence of any commercial or financial
236 relationships that could be construed as a potential conflict of interest.

237 **Funding**

238 This research did not receive any specific grant from funding agencies in the public, commercial, or
239 not-for-profit sectors.

240

241 **References**

- 242 1. Thangaraju P, Gurunthalingam MP, Venkatesan S, Thangaraju E. COVID-19: Wait for a
243 novel drug or act with the age old drug - Do we have a choice? *J Infect Public Health*.
244 2020;13(6):899–900.
- 245 2. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute
246 respiratory syndrome coronavirus by chloroquine. *Biochem Biophys Res Commun*.
247 2004;323(1):264–8.
- 248 3. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of
249 chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*.
250 2020;105938.
- 251 4. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising
252 strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect*.
253 2017;5(1):e00293.
- 254 5. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral
255 infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003;3(11):722–7.
- 256 6. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in
257 treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*.
258 2020;14(1):72–3.
- 259 7. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine
260 and azithromycin as a treatment of COVID-19: results of an open-label non-randomized
261 clinical trial. *Int J Antimicrob Agents*. 2020;105949.
- 262 8. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*. 2020;177:104762.
- 263 9. Tahiri Joutei Hassani R, Bennis A. Hydroxychloroquine as antiviral prophylaxis for exposed
264 caregivers to Covid-19: An urgent appraisal is needed. *J Infect Public Health*.
265 2020;13(6):865–7.
- 266 10. Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
267 *Lancet Infect Dis*. 2020;20(10):1118.
- 268 11. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-
269 19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
270 *Expert Rev Anti Infect Ther*. 2020;55(6):1–12.
- 271 12. Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2
272 infection among patients with systemic autoimmune diseases. *Autoimmunity reviews*.
273 2020;19(7):102575.
- 274 13. Actualización no 123. Enfermedad por el coronavirus (COVID-19). 01.06.2020. Centro de
275 Coordinación de Alertas y Emergencias Sanitarias. Dirección general de salud pública,

- 276 calidad e innovación; Jun 1, 2020 pp. 1–12. Available at:
277 <https://www.msbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov->
278 [China/documentos/Actualizacion_123_COVID-19.pdf](https://www.msbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_123_COVID-19.pdf)
279
- 280 14. Estudio ENE-COVID19: primera ronda estudio nacional de sero-epidemiología de la
281 infección por SARS-COV-2 en España. Informe preliminar 13 de mayo de 2020 . 2020. pp.
282 1–18. Available at:
283 https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_inf_pre.pdf
284
- 285 15. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A
286 Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl*
287 *J Med.* 2020;NEJMoa2016638–9.
- 288




Figure 1.- Percentage of declared COVID-19 cases according to treatment status and community exposition. Treated group refers to patients regularly taking chloroquine and its derivatives. Exposed are those individuals declaring a COVID-19 positive case in a close family member or flatmate. Error bars depict the 95% confidence interval.